Overview
The Molecular Imaging and Therapy (MIT) Clinical Trials and Research Program at BC Cancer serves as a provincial hub for the development, evaluation, and clinical translation of new radiopharmaceuticals and molecular imaging technologies. Our team operates at the intersection of radiochemistry, functional imaging, nuclear medicine physics, and early‑phase therapeutic trials, enabling a seamless pathway from laboratory discovery to first‑in‑human studies. Our clinical trials portfolio includes the assessment of novel PET radiotracers and targeted radioligand therapies, supported by an established infrastructure for PET/CT imaging, regulatory‑approved investigational radiopharmaceutical use, and specialized theranostic trial design. We strive to advance innovation and excellence in cancer care by engaging in impactful clinical research and high-quality clinical trials.
Mission
The Molecular Imaging and Therapy (MIT) Clinical Trials and Research Program advances innovative radiopharmaceutical imaging and therapy through integrated clinical research, quantitative imaging science, and precision dosimetry. The MIT Clinical Trials and Research Program supports the translation of novel PET radiotracers and targeted radioligand therapies from discovery to first‑in‑human trials. Our mission is to deliver safe, effective, and personalized molecular imaging and therapy innovations that improve outcomes for patients across British Columbia.
Leadership
Dr. Don Wilson, Medical Director of Molecular Imaging and Therapy, BC Cancer.
Interested?
To explore collaboration opportunities in theranostics research and clinical trials, please contact our team: mitclinicaltrials@bccancer.bc.ca